Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosamprenavir - Vertex Pharmaceuticals/GSK

Drug Profile

Fosamprenavir - Vertex Pharmaceuticals/GSK

Alternative Names: 433908; 908; GW-433908; Lexiva; Telzir; VX-175

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer GlaxoSmithKline; GSK; Vertex Pharmaceuticals
  • Class Antiretrovirals; Carbamates; Phosphoric acid esters; Small molecules; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 11 Jul 2019 Discontinued - Phase-II for HIV infections (In adolescents, In children) in Romania, Spain, South Africa, Russia, Canada, Belgium, USA (PO) (NDR batch #16)
  • 11 Jul 2019 Discontinued - Phase-II for HIV infections (In infants) in South Africa, Russia, Portugal, Latin America, USA (PO) (NDR batch #16)
  • 03 Sep 2015 Fosamprenavir is still in phase II trials for HIV infections (In infants) in the USA, Latin America, Russia, Portugal and South Africa
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top